Septal Nasal Extramedullary Plasmacytoma: A Rare Tumor in an Unusual Area

Stadio, Arianna Di; Ralli, Massimo; Messineo, Daniela; Ciancia, Giuseppe; Cascone, Annamaria; Salzano, Giovanni; Vincentiis, Marco de; Salzano, Francesco Antonio

doi:10.1177/0145561320911735

Cited by 2 publications

(2 citation statements)

References 6 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…On nasal endoscopy, the tumors present as a fleshy, hyperemic, or hemorrhagic 1868 mass with contact bleeding 1869 . There may be associated superficial ulceration 1870 and necrosis. Larger lesions may cause a visible mass of the maxilla, palate, or orbit 1871…”

Section: Sinonasal Lymphomamentioning

confidence: 99%

International Consensus Statement on Allergy and Rhinology: Sinonasal Tumors

Kuan

Wang

Adappa

et al. 2024

Int Forum Allergy Rhinol

View full text Add to dashboard Cite

BackgroundSinonasal neoplasms, whether benign and malignant, pose a significant challenge to clinicians and represents a model area for multidisciplinary collaboration in order to optimize patient care. The International Consensus Statement on Allergy and Rhinology: Sinonasal Tumors (ICSNT) aims to summarize the best available evidence and presents 48 thematic and histopathology‐based topics spanning the field.MethodsIn accordance with prior ICAR documents, ICSNT assigned each topic as an Evidence‐Based Review with Recommendations, Evidence‐Based Review, and Literature Review based on level of evidence. An international group of multidisciplinary author teams were assembled for the topic reviews using the Preferred Reporting Items for Systematic Reviews and Meta‐Analyses format, and completed sections underwent a thorough and iterative consensus‐building process. The final document underwent rigorous synthesis and review prior to publication.ResultsThe ICNST document consists of 4 major sections: general principles, benign neoplasms and lesions, malignant neoplasms, and quality of life and surveillance. It covers 48 conceptual and/or histopathology‐based topics relevant to sinonasal neoplasms and masses. Topics with a high level of evidence provided specific recommendations, while other areas summarized the current state of evidence. A final section highlights research opportunities and future directions, contributing to advancing knowledge and community intervention.ConclusionAs an embodiment of the multidisciplinary and collaborative model of care in sinonasal neoplasms and masses, ICSNT was designed as a comprehensive, international, and multidisciplinary collaborative endeavor. Its primary objective is to summarize the existing evidence in the field of sinonasal neoplasms and masses.This article is protected by copyright. All rights reserved

show abstract

Section: Sinonasal Lymphomamentioning

confidence: 99%

International Consensus Statement on Allergy and Rhinology: Sinonasal Tumors

Kuan

Wang

Adappa

et al. 2024

Int Forum Allergy Rhinol

View full text Add to dashboard Cite

show abstract

“…1 EMP is a rare subtype of plasmacytoma with an incidence of approximately 0.04 cases per 100,000 which arises from soft tissues and is generally found in the upper aerodigestive tract. [2][3][4] Although EMP only represents around 3% of all plasma cell tumors, 1% of all head and neck tumors, and 4% of all non-epithelial tumors of the sinonasal tract, approximately 80% of cases of EMP occur in the head and neck, with about 75% of these involving the sinonasal cavity. 3,5,6 Common presenting symptoms of sinonasal EMPs (SN-EMP) include nasal obstruction, epistaxis, facial swelling, pain, and rhinorrhea.…”

Section: Introductionmentioning

confidence: 99%

Analysis of the Treatment and Survival of Sinonasal Extramedullary Plasmacytoma

Gao

Tseng

Barinsky

et al. 2022

Am J Rhinol�Allergy

View full text Add to dashboard Cite

Background While extramedullary plasmacytomas are infrequently encountered plasma cell malignancies, most cases occur in the head and neck, with a predilection for the sinonasal cavity. Due to the rarity of this disease, the majority of studies on sinonasal extramedullary plasmacytoma (SN-EMP) are case reports or small retrospective case series. Objective To investigate the impact of patient, disease, and treatment factors on the survival of patients with SN-EMP. Methods The National Cancer Database was queried for all patients with SN-EMP between 2004–2016 (N = 381 cases). Univariate and multivariate analyses were used to examine patient demographics, tumor characteristics, and survival. Results The majority of SN-EMP patients were over 60 years old (57.0%), male (69.8%), and white (86.2%). The most common treatment modality was radiotherapy alone (38.6%), followed by surgery plus radiotherapy (37.8%). Five-year overall survival was 74.0% and median survival was 9.1 years. Accounting for patient demographics and tumor characteristics in a multivariate model, the following groups had worse prognosis: 60 and older (HR 1.99, p = 0.031) and frontal sinus primary site (HR 11.56, p = 0.001). Patients who received no treatment (HR 3.89, p = 0.013), chemotherapy alone (HR 5.57, p = 0.008) or radiotherapy plus chemotherapy (HR 2.82, p = 0.005) had significantly lower survival than patients who received radiotherapy alone. Patients who received surgery with radiotherapy (HR 0.57, p = 0.039) had significantly higher survival than patients who received radiotherapy alone. Conclusion In patients with SN-EMP five-year overall survival was found to be 74.0% with decreased survival associated with a frontal sinus primary site and being aged 60 or older. Patients receiving no treatment, chemotherapy alone, or radiotherapy with chemotherapy was associated with lower survival. Receiving surgery plus radiotherapy was associated with the highest five-year overall survival.

show abstract

Septal Nasal Extramedullary Plasmacytoma: A Rare Tumor in an Unusual Area

Cited by 2 publications

References 6 publications

International Consensus Statement on Allergy and Rhinology: Sinonasal Tumors

International Consensus Statement on Allergy and Rhinology: Sinonasal Tumors

Analysis of the Treatment and Survival of Sinonasal Extramedullary Plasmacytoma

Contact Info

Product

Resources

About